ClinicalTrials.Veeva

Menu

Enhanced Recovery After Surgery in Oblique Lumbar Interbody Fusion

Seoul National University logo

Seoul National University

Status

Completed

Conditions

Lumbar Spondylolisthesis
Lumbar Spinal Stenosis
Spinal Fusion
Enhanced Recovery After Surgery

Treatments

Behavioral: Enhanced Recovery After Surgery program for Oblique Lumbar Interbody Fusion

Study type

Interventional

Funder types

Other

Identifiers

NCT05959343
H-2305-085-1423

Details and patient eligibility

About

This study is a randomized controlled non-inferiority trial designed to evaluate the impact of implementing the 'Early Recovery After Surgery Clinical Pathway (ERAS CP)' on patient-reported pain levels at the time of discharge following Oblique Lumbar Interbody Fusion (OLIF) surgery

Full description

Currently, the effectiveness of the ERAS has been widely confirmed in patients undergoing colorectal resection, and it has been verified to reduce length of hospital stay and complications. However, the ERAS protocol for lumbar fusion surgery is based on a few retrospective studies and remains a consensus statement. Recent retrospective studies targeting patients undergoing lumbar fusion surgery reported that implementing ERAS could accelerate post-operative functional recovery and reduce hospital stay. However, there is still a lack of high-quality evidence based on prospective studies.

Lumbar fusion surgery is known for potentially leading to severe postoperative pain, which poses challenges in consistently applying ERAS components, such as early ambulation or active oral feeding, after surgery. In light of this, the present study aims to validate the non-inferiority of pain levels at discharge within the ERAS group and to reconfirm the effects of ERAS as observed in retrospective studies.

Patients admitted for OLIF will be consecutively screened for eligibility. A computer-generated block randomization will be executed at a 1:1 ratio. In the ERAS group, patients will receive comprehensive education about the treatment process, and a clinical pathway that includes active ambulation and pain control will be protocolized and implemented. Should non-inferiority be demonstrated in both intent-to-treat and per-protocol analyses, non-inferiority will be declared.

Enrollment

38 patients

Sex

All

Ages

40 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Lumbar degenerative disease, requiring interbody fusion of 1-2 segments between L2 and S1

  2. Capability of independent (or assisted) ambulation for at least 30 minutes with

    1. Taking intermittent breaks
    2. Enduring any discomfort
  3. Voluntary informed consent to participate in the study.

Exclusion criteria

  1. Previous history of lumbar interbody fusion
  2. Manual Muscle Testing grade 3 or below
  3. Neuropsychiatric disorders such as major depressive disorder
  4. Musculoskeletal disorders other than lumbar degenerative diseases (inflammatory, myopathic, infections, etc.)
  5. Diagnosis of malignant neoplasm
  6. Refusal to participate in the study

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

38 participants in 2 patient groups

ERAS group
Experimental group
Description:
The experimental group will be implemented with the ERAS Clinical Pathway (ERAS CP)
Treatment:
Behavioral: Enhanced Recovery After Surgery program for Oblique Lumbar Interbody Fusion
Control group
No Intervention group
Description:
The control group will not be implemented with the ERAS CP

Trial contacts and locations

1

Loading...

Central trial contact

Jun-Hoe Kim, MD; Chi Heon Kim, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems